NEW YORK--(BUSINESS WIRE)--Aug. 30, 2006--FermaVir Pharmaceuticals, Inc., (OTCBB:FMVR), announced today that preclinical studies show that its compound for shingles inhibits viral infections exceptionally quickly and that when FV-100 is dosed orally, the active compound shows good dose dependent pharmacokinetics.
